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superficial femoral artery interventions
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Hosam F. El Sayed, MD, Eric K. Peden, MD, Alan B. Lumsden, MD, and
Mark G. Davies, MD, PhD, MBA, Houston, Tex
Background: Metabolic syndrome (MetSyn) is an epidemic in the United States and is associated with early onset of
atherosclerosis, increased thrombotic events, and increased complications after cardiovascular intervention. MetSyn is
found in50% of patients with peripheral vascular disease. However, its impact on peripheral interventions is unknown.
The aim of this study is to determine the outcomes of superficial femoral artery (SFA) interventions in patients with and
without MetSyn.
Methods: A database of patients undergoing endovascular treatment of SFA disease between 1999 and 2009 was
retrospectively queried. MetSyn was defined as the presence of >3 of the following criteria: blood pressure >130 mm
Hg/>85 mm Hg; triglycerides >150 mg/dL; high-density lipoprotein <50 mg/dL for women and <40 mg/dL for
men; fasting blood glucose >110 mg/dL; or body mass index >30 kg/m2. Kaplan-Meier survival analyses were
performed to assess time-dependent outcomes. Factor analyses were performed using a Cox proportional hazard model
for time-dependent variables.
Results: A total of 1018 limbs in 738 patients (64% male, average age 67 years) underwent endovascular treatment for
symptomatic SFA disease with 45% of patients meeting the criteria for MetSyn. MetSyn patients were more likely to be
female (P  .001), to present with critical ischemia (rest pain/tissue loss: 55% MetSyn vs 45% non-MetSyn; P  .001),
have poorer ambulatory status (P  .001), and have more advanced SFA lesions (TransAtlantic Inter-Society Consensus
II C/D: 51% vs 11%; P .001) and worse tibial runoff (P .001). MetSyn patients required more complex interventions
(P .0001). There was no difference in mortality andmajor adverse cardiac events, but systemic complications (4% vs 1%;
P  .001) and major adverse limb events (12% vs 7%; P  .0009) were significantly higher in the MetSyn group.
Immediate postprocedural hemodynamic improvement, resolved or improved symptoms, and restoration of impaired
ambulation were equivalent in both groups. Early failure (<6 months) was more common in those with MetSyn. At 5
years, primary, assisted primary, and secondary patencies were not affected by the presence of MetSyn. The presence of
MetSyn was associated with a decrease in clinical efficacy, decreased freedom from recurrent symptoms, and decreased
freedom from major amputation at 5 years.
Conclusions:MetSyn is present in nearly half of the patients presenting with SFA disease. These patients present withmore
advanced disease and have poorer symptomatic and functional outcomes compared with those patients without MetSyn.
(J Vasc Surg 2012;55:985-93.)
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There has been a substantial increase in the prevalence
of the prediabetic state, metabolic syndrome (MetSyn), and
diabetes mellitus (DM) in the last decade.1 Projections
suggest that these patterns of disease will increase substan-
tially in the next two decades. Coupled to the increase in
diabetic conditions is a marked increase in and shift towards
endoluminal therapy for superficial femoral artery (SFA)
occlusive disease.2,3 The technology and technical skills in
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doi:10.1016/j.jvs.2011.10.109ractice have improved and permitted increasingly more
hallenging lesions to be tackled.4,5 Multiple reports have
emonstrated that presenting symptoms, diabetes, and tib-
al runoff will affect the anatomic and functional outcomes
fter SFA intervention.6-10 We have previously demon-
trated that MetSyn has a negative influence on outcomes
fter carotid intervention and renal intervention.11,12 The
nteraction of MetSyn and SFA interventions is unknown.
he aim of this study is to examine the impact ofMetSyn on
ndoluminal interventions for SFA disease.
ETHODS
Study design. A database of patients undergoing en-
ovascular treatment of SFA disease between 1999 and
009 was retrospectively queried. Two groups were iden-
ified, those with and withoutMetSyn. MetSyn was defined
s the presence of 3 of the following criteria: blood
ressure 130 mm Hg/85 mm Hg; triglycerides 150
g/dL; high-density lipoprotein (HDL) 50 mg/dL for
omen and 40 mg/dL for men; fasting blood glucose
110 mg/dL; or body mass index (BMI) 30 kg/m2.13e substituted a BMI score 30.0 as a positive score
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April 2012986 Smolock et alinstead of an abdominal circumference 102 cm or 88
cm for male or female patients, respectively. Data utiliza-
tion fell under the category of secondary use of pre-existing
data as defined by the Institutional Review Board and the
Health Insurance Portability and Accountability Act
(HIPAA).
Study setting. The setting was an academic medical
center with 1000 beds in a catchment area of 5 million
people. It is a tertiary and quaternary referral facility.
Methodology. For each patient captured, demo-
graphics, symptoms, existing comorbid conditions, and risk
factors for atherosclerosis were identified. Risk factors were
identified for each patient and corrected through their
primary care providers (see Appendix, online only). Ther-
apy for individual patients was dictated by individual at-
tending physician preference and was not regulated by unit
guidelines. All patients received aspirin daily (81 mg or 325
mg) as a general cardiovascular protection agent.
Noninvasive studies were performed initially on all
patients receiving a work-up for peripheral arterial disease.
Patients with serious symptoms or signs of severe stenosis/
occlusion based upon the initial noninvasive tests received
angiograms. Angiograms and angiographic reports were
reviewed; lesions were described by length, calcification,
and patency and then categorized under the TransAtlantic
Inter-Society Consensus (TASC)-II system.14 The preop-
erative distal runoff was scored by the number of patent
tibial vessels and according to a modification of SVS criteria
employed for determining bypass runoff (using the cumu-
lative score for the distal popliteal from knee joint to first
tibial branch; maximum, 9  1) and each of the tibial
vessels (maximum, 3 each) giving a maximum possible total
score of 19.9
Patients were on aspirin preoperatively and in the last 5
years patients also received clopidogrel preoperatively. An-
gioplasty was performed with a patient under systemic
heparin administration (40-60 units/kg), and completion
angiography was performed to assess the technical result.
Stents were utilized (at the discretion of the operator)
primarily or as an adjunct for flow-limiting dissections,
intimal flaps, or poor technical results (50% residual ste-
nosis). No covered stents were used. No procedures or
interventions were performed that could have potentially
jeopardized the outflow vessel for a bypass. The complexity
of each intervention was scored according to the ad hoc
system described by DeRubertis et al6 in which 1 point was
awarded for an intervention in the iliac, femoral, or tibial
segments of the leg.
Patients who had a successful endoluminal intervention
received 75 mg of clopidogrel daily. While a patient was on
clopidogrel, aspirin therapy was maintained at 81 mg per
day. Patients on clopidogrel prior to the intervention re-
mained on clopidogrel after the intervention. Clopidogrel
therapy was continued for 30 days after the intervention.
Patients underwent routine duplex ultrasound follow-up at
1, 3, and every 6 months following their procedure using
criteria previously described.7 During follow-up, angiogra-
phy was only performed if noninvasive studies suggested restenosis/occlusion (positive duplex scan with a drop in
nkle-brachial index [ABI] of0.15 and toe-brachial index
TBI] of 0.1), and the patient had recurrent symptoms.
Statistical analysis. All statistical analyses were per-
ormed on an “intention-to-treat” basis. Measured values
re reported as percentages or means  SD. Patency and
imb salvage rates were calculated using Kaplan-Meier anal-
ses and reported using current SVS criteria and objective
erformance goals.15,16 Cox regression was performed for
ndependent variables. Standard errors are reported in
aplan-Meier analyses. Definitions of all outcome parame-
ers used are shown in the appendix. Analyses were per-
ormed using JMP software version 7.0 (SAS Institute,
ary, NC).
ESULTS
Patient population. A total of 1018 limbs in 738
atients underwent endovascular treatment for symptom-
tic SFA disease and 45% of patients matched the criteria for
etSyn. In the non-MetSyn group, 70% were male, while
n the MetSyn group, 57% were male (Table I); 63% of the
nterventions were for lifestyle-limiting claudication in the
on-MetSyn group, while 45% were performed for this
able I. Characteristics of patients
No MetSyn MetSyn P value
emographics
Patients 408 330 —
Limbs treated 544 474 —
% male 70 57 .001
Average age (mean 
SD, years) 67  15 67  13 .99
ymptoms
Claudication 63% 45%
.001Rest pain/tissue loss 37% 55%
omorbidities
Modified cardiac risk
index 2.8  1.6 3.3  1.7 .001
Smoking history 76% 75% .76
Current smoker 19% 19% 1
Coronary artery disease 35% 43% .01
Hypertension 84% 98% .001
Diabetes 38% 72% .001
Hyperlipidemia 55% 79% .001
Statin 50% 72% .001
Cerebrovascular disease 23% 23% 1
Chronic kidney disease 13% 21% .001
Hemodialysis 5% 14% .001
Hypothyroidism 9% 13% .04
Hypercoagulability 8% 4% .009
reoperative living status
Independent 63% 45% .001
Dependent 37% 55%
reoperative ambulatory
status
Ambulatory 55% 37% .001
Ambulatory/homebound 35% 34%
Nonambulatory/transfer 11% 28%
Nonambulatory/bedridden 0% 1%
etSyn, Metabolic syndrome.eason in those patients withMetSyn. Age was equivalent in
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Volume 55, Number 4 Smolock et al 987both groups (Table I). Past smoking history and current
smoking were equal between the groups (Table I). There
were a significantly higher number of patients with coro-
nary artery disease and a greater modified cardiac risk index
in the MetSyn patients compared with the non-MetSyn
patients (Table I). Hypertension, hyperlipidemia, diabetes,
chronic renal disease, and hypothyroidism were more prev-
alent in those with MetSyn (Table I). There was a twofold
increase in the number of patients on hemodialysis in
MetSyn. Approximately 50% of patients in the non-MetSyn
cohort and 72% in the MetSyn cohort were on statins
(Table I). In MetSyn, there were a higher number of
patients considered dependent and a greater number with a
reduced or nonambulatory status (Table I). Patients pre-
senting with MetSyn had a greater number of TASC-II C
and D lesions (51% vs 31%; P  .001). When traditional
runoff scores were used to grade the runoff, there was no
difference in the group averages between non-MetSyn and
MetSyn (number of tibial vessels, 2.02  0.82% vs 1.92 
0.83%, non-MetSyn vs MetSyn; P .055); however, when
a modified SVS runoff score was used, the runoff in the
MetSyn group was significantly worse (modified SVS run-
off score, 6.6  4.6% vs 7.0  4.5%, non-MetSyn vs
MetSyn; P  .001).
Immediate outcomes. The technical failure rates were
3% and 4% for non-MetSyn and MetSyn, respectively.
However, no patient in either group required emergent
conversion to open surgery. Eventual need for open bypass
surgery is described below (Fig 1,D and E). Approximately
a third of patients in each group required recannulization
for occlusion (Table II). The majority of cases were treated
by angioplasty; however, the use of primary stenting was
twofold higher in the MetSyn group, which may reflect the
aforementioned differences in TASC-II lesion categories.
Overall stent usage was significantly higher in the MetSyn
group (Table II). Patients with MetSyn had a higher level
of complexity in their cases than the non-MetSyn cases
(Table II). An equal number of inflow procedures in the
aortoiliac segment were performed, whereas there were
significantly more tibial interventions in theMetSyn group,
correlating with the previously mentioned poorer runoff
scores. Mortality was equivalent in both groups, despite the
increased burden of coronary disease in the MetSyn group
(Table I). Total morbidity was similar between the two
groups, but there was an increase in the incidence of
systemic complications in the MetSyn group (Table III).
Thirty-day major adverse cardiac events (MACE) were
equivalent but 30-day major adverse limb events (MALE)
were higher in the MetSyn group compared with the non-
MetSyn group (Table III).
Hemodynamically, there was a marked increase in ABIs
in both groups, with more than 80% of patients having a
rise in their ABI of0.15. There was no difference between
non-MetSyn and MetSyn groups (Table IV). Following
intervention in non-MetSyn and MetSyn groups, 83% and
87% of patients were considered to have improved or
resolved symptoms, respectively (Table IV). There was a
significant improvement in ambulatory status in both troups after intervention and both groups had equivalent
esponses (Table IV). There was no difference in discharge
tatus between the groups (Table IV).
Long-term anatomic outcomes. There was no signif-
cant difference in the primary (67%  3% vs 61  4%,
on-MetSyn vs MetSyn; P .06), assisted primary (77%
% vs 73% 4%; P .19), or secondary patency (78% 2%
s 77  3%; P  .27) of the non-MetSyn and MetSyn
roups at 5 years (Fig 1, A-C). There was a significant
ssociation (P .03) with early failure (6 months) in the
etSyn group (61%) compared with the non-MetSyn
roup (47%). Target vessel revascularization (TVR, 81% 
% vs 79%  3%, non-MetSyn vs MetSyn; P  .14) and
arget extremity revascularization (TER), 79%  2% vs
7 3%, non-MetSyn vs MetSyn; P.10) were equivalent
t 5 years (Fig 1, D and E).
Long-term functional outcomes. Overall mortality
as higher in the MetSyn group, with patient survival rates
f 71%  2% and 53%  3% at 5 years in the non-MetSyn
nd MetSyn groups, respectively (Fig 2, A). Amputation-
ree survival was significantly worse in the MetSyn group
Fig 2, B). Freedom from recurrent symptoms was superior
n the non-MetSyn group (Fig 2, D). The 5-year rate of
reedom from recurrent symptoms was 62%  2% and
1%  6% in the non-MetSyn and MetSyn groups, respec-
ively (P .03). Limb salvage was significantly better in the
on-MetSyn group compared with the MetSyn group (Fig
, C). The 5-year limb salvage rate was 90%  2% and
4%  3% in the non-MetSyn and MetSyn groups, respec-
ively. Three percent and 8% of patients presenting with
laudication in the non-MetSyn and MetSyn groups, re-
pectively, suffered a major amputation (P  .23), while
7% and 48% presenting with critical limb ischemia in the
on-MetSyn and MetSyn groups suffered a major amputa-
ion (P  .02). Clinical success defined as freedom from
ecurrent symptoms,maintenanceof ambulation, and absence
f amajor amputationwas significantly higher (60% 3% and
9%  5% at 5 years) in the non-MetSyn group compared
ith the MetSyn group (Fig 2, E).
A Cox regression subanalysis was performed on both
etSyn and non-MetSyn groups for complexity score/
ultilevel intervention as well as patient factors creatin-
ne 2, hemodialysis, and TASC C/D. Each was censored
y the following: primary patency, assisted primary patency,
econdary patency, survival, freedom from recurrent symp-
oms, and clinical efficacy. Complexity score/multilevel
ntervention was an independent risk factor in freedom
rom recurrent symptoms (P  .01) and clinical efficacy
P .003). Creatinine  2 was an independent risk factor
n status of limb/toe amputation or greater freedom from
mputation and amputation-free survival (P  .02).
ISCUSSION
Summary. In this study, we analyzed the presence of
etSyn and its relationship to short- and long-term out-
omes in 738 patients undergoing SFA interventions for
ymptomatic lower extremity arterial disease. We found
hat MetSyn patients were more likely to be female, to
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April 2012988 Smolock et alpresent with critical ischemia (rest pain/tissue loss), have
poorer ambulatory status, have more advanced SFA lesions,
and have worse tibial runoff (P  .001). Patients with
Fig 1. Anatomic outcomes: Life table analysis of patient
standard error of the mean and number of limbs at risk sh
of the mean is 10%, and the data set terminates if the n
patency; C, secondary patency; D, target vessel revasculaMetSyn required more complex interventions (P .0001). Mhere was no difference in mortality and MACE, but
ystemic complications (4% vs 1%; P  .001) and MALE
12% vs 7%; P  .0009) were significantly higher in the
and without metabolic syndrome. Data are the mean
n the table. No error bars are shown if the standard error
r at risk is 10. A, Primary patency; B, assisted primary
on; and E, target extremity revascularization.s with
own i
umbeetSyn group. Immediate postprocedural hemodynamic/
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Volume 55, Number 4 Smolock et al 989symptom improvement and restoration of impaired ambu-
lation were equivalent in both groups. Early failure (6
months) was more common in those with MetSyn. At 5
Table II. Procedures and complexity
No MetSyn MetSyn P value
Intervention
Recannulization 36% 33% .32
Angioplasty 67% 58% .008
Primary stenting 15% 24%
Laser and directional
atherectomy 3% 5%
Stent usage 31% 43% .002
Adjunctive interventions
Aortoiliac
intervention 9% 9% 1.0
Tibial intervention 7% 18% .001
Complexity score 1.21  0.44 1.37  0.57 .0001
MetSyn, Metabolic syndrome.
Table III. Mortality, morbidity, and objective
performance goals
No MetSyn MetSyn P value
Mortality and morbidity
Mortality 2.8% 1.7% .29
Morbidity 15% 15% 1
Systemic 1% 4% .001
Local 6% 4% .16
Lesion 13% 14% .65
Objective performance goals
30-day MACE 2.9% 2.1% .55
30-day MALE 7% 12% .009
MACE, Major adverse cardiac events; MALE, major adverse limb events;
MetSyn, metabolic syndrome.
Table IV. Hemodynamic changes and immediate
symptom relief
No MetSyn MetSyn P value
Hemodynamic changes
Change in ABI 0.25  0.32 0.28  0.33 .14
% ABI increase 0.15 80% 82% .42
Immediate symptom relief
Resolved 48% 42% .002
Improved 35% 45%
No change 16% 11%
Deterioration 1% 2%
Postoperative ambulatory
status
Ambulatory 86% 81% .26
Ambulatory/homebound 7% 9%
Nonambulatory/transfer 7% 9%
Nonambulatory/bedridden 0% 1%
Discharge status
Home 75% 76% .70
Rehabilitation facility 17% 15%
Skilled nursing facility 7% 8%
Hospital 1% 1%
ABI, Ankle-brachial index; MetSyn, metabolic syndrome.years, primary, assisted primary, and secondary patencies mere not affected by the presence of MetSyn. This may
ndicate the most likely time frame that MetSyn interven-
ion will fail anatomically, within 6 months, though there is
o significant difference between the groups at 5 years in
egards to arterial patency to the ankle. The presence of
etSyn was associated with lower survival, a decrease in
linical efficacy, reduced freedom from recurrent symp-
oms, and diminished freedom frommajor amputation at 5
ears.
Patients. MetSyn was found in 45% of patients pre-
enting with symptomatic SFA disease. A survey of patients
ith intermittent claudication and ABI 0.90 showed that
3% met the revised version of the Adults Treatment Panel
II (rATP III) criteria for MetSyn.17 In women, MetSyn is
ssociated with an increased risk of future symptomatic
eripheral arterial disease. The prevalence of MetSyn in the
eneral adult population in developing countries has been
stimated to be between 22% and 39% and varies depend-
ng on the definition used and on ethnicity.18-20 Using
ither World Health Organization (WHO) or National
holesterol Education Program (NCEP) definitions, Met-
yn is associated with future coronary heart disease events
nd type 2 diabetes. Both definitions will predict cardiovas-
ular mortality, while the NCEP definition can predict
ll-cause mortality. People withMetSyn and a Framingham
isk score 20% have an increased risk of major coronary
vents over the next 10 years compared with people with-
ut MetSyn and the same risk score.21 Well-established
ndicators of the increased cardiovascular risk, such as low
BI and increased C-reactive protein (CRP) levels, also
luster with MetSyn.22 We found that the overall mortality
as significantly much higher in the MetSyn group than in
he non-MetSyn group. The patients that had a higher
aseline modified cardiac risk index and the morbidities
ssociated with cardiovascular mortality were clustered in
he MetSyn group. These included the diseases associated
ith MetSyn (hypertension, hyperlipidemia, and diabetes)
nd those not associated with MetSyn (chronic renal insuf-
ciency, hemodialysis dependency, and hypothyroidism).
his clustering of comorbidities was associated with a lower
evel of independence and mobility. Many of these findings
re associated with presence of obesity.
Metabolic syndrome. Identification of MetSyn al-
ows clinicians to move away from a strategy based on
anagement of a single risk factor to one that focuses on a
onstellation of synergistic risk factors.23 There are, how-
ver, multiple definitions of MetSyn.13,24 Our definition is
imilar to the NCEP definition in the scoring system for
our of the five criteria.25We substituted abdominal obesity
ith a BMI30 kg/m2. Due to the retrospective design of
ur study, we did not have abdominal circumference data
or the patients in the study groups. The WHO definition
f MetSyn permits substituting an elevated BMI for ab-
ominal obesity.
Presentation. In this study, we found that the patients
ith MetSyn presented with more advanced symptoms of
est pain and tissue loss than those without MetSyn; the
ore significant symptoms were reflected in more ad-
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April 2012990 Smolock et alvanced anatomic disease (greater number of TASCC andD
lesions) and a poorer tibial runoff. Maksimovic et al26 have
shown that the degree of peripheral arterial disease clinical
Fig 2. Functional outcomes: Life table analysis of patien
standard error of the mean and number of patients or lim
standard error of the mean is 10% and the data set
amputation-free survival; C, limb salvage; D, freedom frmanifestations is not related to gross MetSyn score, a lnding we also noted in this study. However, gangrene was
ignificantly positively associated with increased fasting glu-
ose, high-sensitivity CRP (hsCRP), and lower education
h andwithoutmetabolic syndrome.Data are themean
t risk shown in the table. No error bars are shown if the
inates if the number at risk is 10. A, Survival; B,
current symptoms; and E, clinical success.ts witevels.26 We have shown that the presence of diabetes and
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Volume 55, Number 4 Smolock et al 991chronic renal insufficiency will affect the outcomes after
SFA intervention.7,8 Several other authors have demon-
strated that the severity of presenting symptoms,27,28 lesion
severity,28,29 and the poor runoff will affect the outcomes
of SFA interventions.9,29
Anatomic outcomes. The presence ofMetSyn did not
influence the overall technical success of the procedures,
but the procedures were more frequently multilevel and
required a higher number of recanalizations and stent
placements. This reflects the presence of themore advanced
disease. MetSyn patients were more likely to fail early,
within the first 6 months, which has been shown to be a
poor predictor of the success of further interventions in the
SFA.30,31 Anatomically, this is similar to studies of inter-
ventions in other vessels, namely the renal and coronary
arteries,12,32,33 where the presence of MetSyn did not
influence the anatomic outcomes. Overall mortality and
morbidity was equivalent after intervention between the
groups, with the exception that the MetSyn group experi-
enced more systemic complications. Thirty-dayMACE was
equivalent but 30-day MALE was high in the MetSyn
group compared with the non-MetSyn group; this was not
driven by major amputations at 30 days, as this was equiv-
alent between the groups. Similar findings have been seen
in the coronary and renal literature.12,34
Functional outcomes. Functional outcomes, namely
reduction in symptoms, preservation of limb, and mainte-
nance of ambulation must remain the ultimate goal of all
vascular interventions, including those in the SFA. There has
been a decrease in major amputations reported in the Nation-
wide Inpatient Sample (NIS) associated with an increase in
endoluminal interventions and a decrease in surgical proce-
dures over the past few decades for a variety of reasons.35 The
most significant finding in this study is that the presence of
MetSyn portends a worse functional outcome for SFA inter-
ventions. The presence of obesity and MetSyn significantly
increased the risks of subsequent cardiac events among pa-
tients who underwent percutaneous coronary interven-
tion.36-40 Similar poor functional outcomes have been seen
after renal interventions in patients with MetSyn.12 Patients
with MetSyn had an overall poorer clinical efficacy (freedom
from recurrent symptoms, maintenance of ambulation, and
absence of a major amputation) than those without MetSyn.
This was despite the fact that therewere an equivalent number
of patients showing an ABI rise 0.15 combined with the
majority of the patients showing initial improvement or reso-
lution of symptoms, respectively. These changes in symptoms
were coupled with a significant improvement in ambulatory
status in both groups. Long-term mortality was higher and
amputation-free survival was significantlyworse in theMetSyn
group. Notably this lower amputation-free survival was also
true for MetSyn patients with claudication only and no rest
pain/tissue loss. This not only reinforces the authors’ practice
of reserving interventions in claudicants for those with subjec-
tively severe and disabling claudication that limits the patient’s
activity such that it is exacerbating existing comorbidities. It
also adds further caution in proceeding with intervention in
claudicants with MetSyn going forward. This reflects theighermodified cardiac risk index and cluster of comorbidities
nd the greater number of patients presenting with critical
imb ischemia and advanced anatomic disease. It must also
eflect the presence of diabetes and hemodialysis conditions in
he MetSyn patients. While the immediate improvements in
resenting symptoms were gratifying, the freedom from re-
urrent symptoms and limb salvage were worse, with 27% of
on-MetSyn patients and 48% of MetSyn patients presenting
ith critical limb ischemia suffering a major amputation dur-
ng follow-up.
Study limitations. This study is retrospective in na-
ure and the clinical decision making was individualized,
ot driven by a standard protocol. The definitions of Met-
yn are continually changing, and we have used a surrogate
arker of body adiposity (BMI calculation from admission
eight and weight) that is not currently utilized in all
efinitions of MetSyn. We cannot discount completely the
nfluence of diabetes, obesity, and end-stage renal disease
n the results, but it appears that patients with MetSyn
ffectively cluster the worst comorbidities to them at pre-
entation.
ONCLUSIONS
Patients with MetSyn present with more advanced
ymptoms, more complex atherosclerotic disease, and re-
uire more complex interventions. While anatomic out-
omes are not influenced by MetSyn, functional outcomes
reduction in symptoms, preservation of limb, and mainte-
ance of ambulation) are worse and long-term survival is
horter. MetSyn should be considered a risk factor for poor
utcomes during SFA interventions.
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aDISCUSSION
Dr Scott Stevens (Knoxville, Tenn). This presentation from
Smolock, Lumsden, Davies and Team Vascular at TheMethodist/
DeBakey Heart & Vascular Center in Houston addresses the
important topic of outcomes for SFA interventions in patients with
metabolic syndrome. They studied 1014 SFA interventions over a
10-year period and found that nearly half of these were in patients
with metabolic syndrome. Their study showed that in this subset,
patients with metabolic syndrome were more likely to be female,
have more advanced lesions, and present with critical limb
ischemia. The study also demonstrated higher morbidity and
decreased clinical efficacy, as manifest by recurrent symptoms,
decreased patency, and more amputations. Of note, periproce-
dural mortality was not increased in patients with metabolic
syndrome. This study is important because it addresses out-
comes in the arena of lower extremity interventions and in the
era of comparative effectiveness, it is going to be all about
outcomes. Despite the huge increase of SFA interventions and
the wide array of therapeutic options available, we still have no
evidence-based data to guide us. It is pivotal that, as vascular
surgeons, we step up and participate in registries, trials, and critical
outcomes analysis to continue our leadership position and bring
the best treatment for our patients.
I would like to congratulate Dr Smolock and the vascular team
at The Methodist/DeBakey Heart & Vascular Center in Houston
for an excellent and timely paper.
Chris, I have four questions:
1. Your data showed higher periprocedural morbidity and worse
long-term outcomes, but not worse periprocedural mortality in
the patients with metabolic syndrome – any ideas why?
2. Do you think metabolic syndrome in this study was a surrogate
for anatomic and morphologic predictors of poor outcomes or
does it represent a systemic effect?
3. Because of worse outcomes in patients with metabolic syndrome,
have you raised the threshold for intervention in this subset?
4. Considering your results, what changes have you made in your
practice to reduce vascular risk factors in patients with meta-
bolic syndrome? iDr Christopher J. Smolock. Thank you, Dr Stevens. For
ortality, it was the same between the groups in the periprocedural
eriod. However, mortality was significantly higher for the meta-
olic syndrome group over the 5-year period. I think the similar
nd low mortality in the 30-day period reflects the fact that these
ere local procedures not done under general anesthesia. There
re some negative reports regarding patients with metabolic syn-
rome undergoing coronary procedures as well as general surgery
rocedures. This is attributed to these patients receiving general
nesthesia with a higher likelihood of systemic complications. We
id still see a systemic effect in our complication rate in the
eriprocedural period and that was not due to local complications
ut rather cardiac, renal, pulmonary, and other systemic types of
omplications. I also hope that the low periprocedural mortality
as to do with our risk reduction strategies preoperatively. This
lso leads into your last question about what we did differently. We
ound that our use of statins, -blockers, and aspirin were not at
he levels we would like them to be. Therefore, we have focused on
nitiating and maintaining these medications when appropriate on
ll of our patients preoperatively, perioperatively, and upon dis-
harge. In addition, if they meet criteria, we offer referral to a
ariatric center. Regarding your second question about small
argets, I do not think that the difference with metabolic syndrome
s due to poor or small targets. That is based on some of the data we
howed related to runoff score. By number of tibial vessels, which
as been related to better outcomes, there was no difference
etween the groups. There was also no difference between groups
s measured by SVS runoff score. Diabetes of course is a risk by
tself for poor targets or small targets so there may be something
here, but not that you could measure anatomically by the afore-
entioned metrics. And finally, regarding the general approach of
he group to intervening for this disease process, we try to be
onservative for claudication, unless it is life altering. We are
ggressive with an endovascular approach as a first line for critical
schemia.
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Definitions. Coronary artery disease was defined as a
history of angina pectoris, myocardial infarction, conges-
tive heart disease, or prior coronary artery revasculariza-
tions. Cerebrovascular disease was defined as a history of
stroke, transient ischemic attack, or carotid artery revascu-
larization. Chronic renal impairment was defined as an
eGFR 60 mL/min/1.73 m2 or patient on dialysis. Hy-
pertension was defined as a systolic blood pressure 150
mm Hg or diastolic blood pressure 90 mm Hg on three
occasions during a 6-month period. Hypercholesterolemia
was defined as fasting serum concentrations of cholesterol
200mg/dL, a LDL130mg/dL, or triglycerides200
mg/dL. Diabetes was defined as a fasting plasma glucose
110 mg/dL or an HbA1c 7%. Non-insulin-dependent
diabetes mellitus was defined as any patient with diabetes
mellitus who did not routinely receive insulin therapy for
their diabetes management. Insulin-dependent diabetes
mellitus was defined as any patient with diabetes mellitus
who routinely received insulin therapy. Modified cardiac
risk index was used to classify the preoperative risk of major
cardiac events through a point system based on patient
history and physical examination as well as the proposed
intervention.41 TASC-II classification of disease severity for
femoral lesions was used to define the categories of le-
sions.14 A death within 30 days of the procedure was
considered procedure related. A major complication was
defined as any event, regardless of how minimal, not rou-
tinely observed after endoluminal therapy that required treatment with a therapeutic intervention or rehospitaliza-
ion within 30 days of the procedure. Systemic complica-
ions were those related to cardiac, pulmonary, or renal
ystems as well as sepsis. Local complications were those
elated to access site, surgical wounds, and the treated limb.
ACE was defined as a myocardial infarction, stroke, or
eath (any cause) within 30 days.16 Pre- and postproce-
ural symptoms were defined by SVS criteria15 and a drop
n symptom score of 1 or more in follow-up was considered
ecurrent symptoms. MALE was defined as an above-ankle
mputation of the index limb or major reintervention (new
ypass graft, jump/interposition graft revision, or throm-
ectomy/thrombolysis) within 30 days.16 Primary, assisted
rimary, and secondary patency rates were defined in accor-
ance with the reporting standards of the SVS.15 Freedom
rom TVR was considered the absence of a percutaneous
eintervention or bypass on the initial target vessel or major
psilateral amputation of the index limb. Freedom from
ER was considered the absence of a percutaneous reinter-
ention/bypass on or major ipsilateral amputation of the
ndex limb. Freedom from recurrent symptoms was consid-
red the absence of recurrent ipsilateral symptoms in or
eed for ipsilateral amputation of the index limb. 9 Limb
alvage was considered the freedom from ipsilateral major
mputation of the index limb.15 Amputation-free survival
as defined as freedom from above-ankle amputation of
he index limb or death. Clinical efficacy was defined as the
bsence of recurrent symptoms, maintenance of ambula-
ion, and limb preservation in the index limb.
